Ownership and insider activity for Tenaya Therapeutics, Inc. (TNYA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small mol...
Price
| Price | $0.66 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.9M | $128.5M | $38.1M | $95.3M | $45.7M | $4.3M | $100.5M |
| Short-term Investments | $2.8M | 0 | $213.2M | $91.3M | $59.0M | $57.1M | 0 |
| Receivables | 0 | 0 | 0 | $2.2M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $27.7M | $130.0M | $255.4M | $193.8M | $111.6M | $67.4M | $105.6M |
| Property, Plant & Equipment | $9.6M | $17.2M | $54.7M | $62.7M | $53.3M | $47.7M | $37.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $38.0M | $148.2M | $316.6M | $278.9M | $170.5M | $119.9M | $146.9M |
| Accounts Payable | $600000 | $1.0M | $10.7M | $9.6M | $5.6M | $5.2M | $3.6M |
| Short-term Debt | 0 | 0 | $2.0M | 0 | 0 | $2.8M | 0 |
| Total Current Liabilities | $4.1M | $5.0M | $21.8M | $24.2M | $22.7M | $16.0M | $15.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $7.8M |
| Total Liabilities | $81.7M | $8.7M | $38.1M | $35.6M | $31.1M | $27.1M | $23.7M |
| Retained Earnings | -$44.4M | -$82.8M | -$155.5M | -$279.2M | -$403.3M | -$514.4M | -$605.0M |
| Total Equity | -$43.7M | $139.4M | $278.5M | $243.4M | $139.4M | $92.9M | $123.3M |
| Total Debt | 0 | 0 | $15.7M | $15.1M | $12.4M | $13.6M | $10.8M |
| Net Debt | -$26.6M | -$128.5M | -$235.6M | -$171.4M | -$92.2M | -$47.8M | -$89.7M |
| Working Capital | $23.6M | $124.9M | $233.6M | $169.5M | $88.8M | $51.4M | $90.2M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 4.52 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -4.36 |
Profitability
| Return on Equity | -108.05% |
| Return on Invested Capital | -136.78% |
| Return on Assets | -110.24% |
| Gross Margin | 263.67% |
| Operating Margin | -7929.89% |
| Net Margin | -7723.97% |
Related companies: ABEO · CRBU · ENTA · FHTX · HUMA · IMRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of TNYA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks